Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
24 September 2024 | Story Aimée Barlow | Photo Supplied
Louzanne Coetzee - 2024
Louzanne Coetzee, who made history by clinching South Africa’s second medal at the Paralympics, earning a bronze in the T11 1 500 m women’s final with a personal best time, received a warm reception when she recently returned home.

The celebrated Paralympic bronze medallist Louzanne Coetzee returned home to a warm welcome at the Bram Fischer International Airport on 10 September 2024.

Family, friends, colleagues, Arista students, and media gathered to celebrate her remarkable achievement and show their support.

Coetzee – KovsieSport Coordinator of Parasport at the University of the Free State (UFS) – made history by clinching South Africa’s second medal at the Paralympics, earning a bronze in the T11 1 500 m women’s final with a personal best time. Her dedication and hard work have not only brought her personal glory but have also inspired many in her community.

Among those present to welcome her was Jerry Laka, Director of KovsieSport, who expressed his pride in Coetzee’s accomplishments.

"We as KovsieSport are so proud of our colleague Coetzee. It is amazing to see a product of KovsieSport achieving greatness on the world stage. She is truly an inspiration to us all," said Laka.

“I am so glad to be back, and to have Laka and my colleagues here. It means the world to me. Having Laka here shows his commitment to my career and ParaSport and his staff in general,” shared Coetzee, her gratitude evident.

She further expressed her appreciation for the support she received, stating, “I don’t have the words to describe how thankful I am for the support from the UFS community.”

Coetzee’s return is a proud moment for South Africa and the University of the Free State (UFS) community. Welcome home, Louzanne! Your achievements have made us all proud!

News Archive

#Women'sMonth: Save the children
2017-08-10

Description: Trudi O'Neill Tags: : rotaviruses, young children, Dr Trudi O’Neill, Department of Microbial, Biochemical and Food Biotechnology, vaccine 

Dr Trudi O’Neill, Senior lecturer in the Department of
Microbial, Biochemical and Food Biotechnology.
Photo: Anja Aucamp

Dr Trudi O’Neill, Senior lecturer in the Department of Microbial, Biochemical and Food Biotechnology, is conducting research on rotavirus vaccines.

Dr O’Neill was inspired to conduct research on this issue through her fascination with the virus. “The biology of rotaviruses, especially the genome structure and the virus’ interaction with the host, is fascinating.”

“In fact, it is estimated that, globally, ALL children will be infected with rotavirus before the age of five, irrespective of their socio-economic standing. However, infants and young children in poor countries are more vulnerable due to inadequate healthcare. The WHO estimates that approximately 215 000 deaths occur each year. This roughly equates to eight Airbus A380 planes, the largest commercial carrier with a capacity of approximately 500 seats, filled with only children under the age of five, crashing each week of every year.”

Alternative to expensive medicines 
“Currently, there are two vaccines that have been licensed for global use. However, these vaccines are expensive and poor countries, where the need is the greatest, are struggling to introduce them sustainably. It is therefore appealing to study rotaviruses, as it is scientifically challenging, but could at the same time have an impact on child health,” Dr O’Neill said.

The main focus of Dr O’Neill’s research is to develop a more affordable vaccine that can promote child vaccination in countries/areas that cannot afford the current vaccines.

All about a different approach 

When asked about the most profound finding of her research, Dr O’Neill responded: “It is not so much a finding, but rather the approach. My rotavirus research group is making use of yeast as vehicle to produce a sub-unit vaccine. These microbes are attractive, as they are relatively easy to manipulate and cheap to cultivate. Downstream production costs can therefore be reduced. The system we use was developed by my colleagues, Profs Koos Albertyn and Martie Smit, and allows for the potential use of any yeast. This enables us to screen a vast number of yeasts in order to identify the best yeast producer.”

Vaccination recently acquired a bad name in the media for its adverse side effects. As researcher, Dr O’Neill has this to say: “Vaccines save lives. By vaccinating your child, you don’t just protect your own child from a potentially deadly infection, but also other children in your community that might be too young to be vaccinated or have pre-existing health problems that prevents vaccination.” 

A future without rotavirus vaccination?

Dr O’Neill believes a future without rotavirus vaccination will be a major step backwards, as the impact of rotavirus vaccines has been profound. “Studies in Mexico and Malawi actually show a reduction in deaths. A colleague in Mozambique has commented on the empty hospital beds that amazed both clinicians and scientists only one year after the introduction of the vaccine in that country. Although many parents, mostly in developed countries, don’t have to fear dehydrating diarrhoea and potential hospitalisation of their babies due to rotavirus infection anymore, such an infection could still be a death sentence in countries that have not been able to introduce the vaccine in their national vaccination programmes,” she said. 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept